Skip to main content
  • Pediatric Ophth/Strabismus

    Review of: Outcomes of inferior oblique myectomy versus recession combined with lateral rectus recession in V-pattern exotropias

    Bolton E, Cheng O, Rossen J, et al. Journal of American Association for Pediatric Ophthalmology and Strabismus, December 2023

    The efficacy of bilateral inferior oblique (BIO) myectomy vs BIO recession, in combination with bilateral rectus (BLR) recession, in children with V-pattern exotropia has not been well studied.

    Study Design

    This was a retrospective review of records from 50 pediatric patients who underwent BLR recession with either BIO myectomy or BIO recession for V-pattern exotropia with bilateral inferior oblique overaction (IOOA). Outcomes were final horizontal and vertical deviations, residual V pattern, control of residual horizontal deviation, and residual IOOA.

    Outcomes

    Both BIO myectomy and BIO recession, in conjunction with BLR recession, decreased the exotropia. However, myectomy had a greater effect on decreasing the V pattern and inferior oblique overaction, particularly in patients who had ≥15Δ of vertical incomitance at baseline. In addition, patients undergoing myectomy demonstrated better control of residual horizontal strabismus than patients undergoing BIO recession.

    Limitations

    This was a retrospective review, but the decision to use BIO myectomy vs BIO recession was based on surgeon practice and not patient characteristics. Two surgeons employed myectomy while 6 surgeons employed recession.

    Clinical Significance

    When coupled with BLR recession, BIO myectomy had a greater effect than BIO recession on decreasing the V-pattern, decreasing residual IOOA overaction, and improving residual strabismus control in patients with V-pattern exotropia. Further studies with larger populations may be needed to confirm these findings.

    Financial Disclosures: Dr. Laura Enyedi discloses financial relationships with Cooper Vision, Novartis (Consultant/Advisor), Ocular Therapeutix (Grant Support), Sophia Pharma (Lecture Fees/Speakers Bureau), and Wolters Kluwer Health (Patents/Royalty).